MPT0B098
MPT0B098 is a microtubule inhibitor with a Ki of 0.8 μM and an IC50 of 0.8 μM. MPT0B098 inhibits tubulin polymerization, blocks HuR nuclear-cytoplasmic translocation to decrease HIF-1α mRNA stability, suppresses HIF-1α, TGF-β/Smad, JAK2/STAT3 and FAK/actin cytoskeleton signaling pathways, upregulates SOCS3 to reinforce the inhibition of JAK2/STAT3 cascade, and induces apoptosis. MPT0B098 can be used for research on multiple malignancies including head and neck squamous cell carcinoma and human non-small cell lung cancer.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 1254363-89-7
- Formule: C20H18N2O3S
- Masse moléculaire:366.44
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
|
microtubule 0.8 μM (IC50) |
microtubule 0.8 μM (Ki) |
HIF-1α |
TGF-beta/Smad |
JAK2 |
STAT3 |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HT-29 | IC50 |
87.5 nM
Compound: 19
|
Antiproliferative activity against human HT-29 cells assessed as inhibition of cell growth after 72 hrs by methylene blue dye assay
Antiproliferative activity against human HT-29 cells assessed as inhibition of cell growth after 72 hrs by methylene blue dye assay
|
10.1039/C0MD00052C |
| KB | IC50 |
96 nM
Compound: 19
|
Antiproliferative activity against human KB cells assessed as inhibition of cell growth after 72 hrs by methylene blue dye assay
Antiproliferative activity against human KB cells assessed as inhibition of cell growth after 72 hrs by methylene blue dye assay
|
10.1039/C0MD00052C |
| MKN-45 | IC50 |
69.5 nM
Compound: 19
|
Antiproliferative activity against human MKN45 cells assessed as inhibition of cell growth after 72 hrs by methylene blue dye assay
Antiproliferative activity against human MKN45 cells assessed as inhibition of cell growth after 72 hrs by methylene blue dye assay
|
10.1039/C0MD00052C |
| NCI-H460 | IC50 |
101 nM
Compound: 19
|
Antiproliferative activity against human H460 cells assessed as inhibition of cell growth after 72 hrs by methylene blue dye assay
Antiproliferative activity against human H460 cells assessed as inhibition of cell growth after 72 hrs by methylene blue dye assay
|
10.1039/C0MD00052C |
MPT0B098 inhibits proliferation of multiple human cancer cell lines, including H460, A549, H1299, HONE-1, PC-3, KB, HT29 and MKN-45 cells, with IC50 values of 78-150 nM, while HUVEC cells are less sensitive to MPT0B098 with an IC50 of 510 nM[1].
MPT0B098 inhibits tubulin polymerization with a Ki of 0.8 μM, and with an IC50 of 0.8 μM[1].
MPT0B098 (0-1000 nM; 24 h) induces G2/M phase arrest and apoptosis in A549 cells by increasing cyclin B1 and MPM2, changing Cdc25C and Cdc2 phosphorylation, increasing TUNEL-positive cells, promoting Bcl-2 phosphorylation and inducing PARP cleavage[1].
MPT0B098 (0.2-0.5 μM; 16 h) inhibits VEGF-induced capillary-like tube formation in HUVECs[1].
MPT0B098 (0.25 μM; 24 h) inhibits VEGF-induced HUVEC migration without reducing HUVEC viability[1].
MPT0B098 (0-2 μM; 18 h) concentration-dependently reduces intracellular VEGF protein and secreted VEGF level in HUVECs; 0-0.9 μM MPT0B098 (18 h) suppresses hypoxia-induced VEGF secretion from A549 cells[1].
MPT0B098 (0-0.9 μM; 18 h) decreases HIF-1α protein and produced stronger growth inhibition and higher caspase-3 activity under hypoxia, destabilizes HIF-1α mRNA, and reduces HuR nuclear-to-cytoplasmic translocation in A549 cells[1].
MPT0B098 (111-444 nM; 72 h) suppresses proliferation of OEC-M1 cells under normoxia and hypoxia, with IC50 of 222 nM under normoxia and IC50 of 265 nM under hypoxia[2].
MPT0B098 (111-444 nM; 18 h) dose-dependently downregulates HIF-1α protein, blocks hypoxia-triggered F-actin cytoskeleton rearrangement and reduces hypoxia-induced FAK phosphorylation without changing total FAK protein in hypoxic OEC-M1 cells[2].
MPT0B098 (111-444 nM; 18-36 h) suppresses EMT transcription factors Twist and SNAI2/Slug in hypoxic OEC-M1 cells[2].
MPT0B098 (111-444 nM; 36 h) downregulates vimentin and N-cadherin while partially restoring E-cadherin, suppresses TGF-β protein expression and Smad2/3 phosphorylation, and reduces TGF-β1 and TGF-β2 mRNA levels in hypoxic OEC-M1 cells[2].
MPT0B098 (111-444 nM; 18 h pretreatment + TGF-β 18 h co-stimulation) reverses TGF-β-triggered Smad2/3 phosphorylation in hypoxic OEC-M1 cells[2].
MPT0B098 (111 nM; 48 h) reverses hypoxia-induced mesenchymal morphological transformation of OEC-M1 cells[2].
MPT0B098 (111 nM; 4-18 h) inhibits hypoxia-induced OEC-M1 cell migration in a time-dependent manner without obvious cytotoxicity[2].
MPT0B098 (0.12-0.5 μM; 72 h) concentration-dependently suppresses viability of multiple OSCC cell lines (OEC-M1, HSC-3, SCC-25, Tu183, DOK, YD-15) with IC50 of 0.14-0.45 μM, while normal HOK cells exhibit weak sensitivity with IC50 of 6.3 μM[3].
MPT0B098 (0.25 μM; 0-60 min) induces time-dependent tubulin depolymerization in OEC-M1 and HSC-3 cells, and microtubule network can partially recover after drug washout for 60 min[3].
MPT0B098 (0.25, 0.5 μM; 12 h) triggers dose-dependent G2/M cell cycle arrest and Annexin V-positive early apoptosis in OEC-M1 cells[3].
MPT0B098 (0.12-1 μM; 24 h) elevates cleaved caspase-3 and PARP, and downregulates anti-apoptotic proteins Bcl-2, Mcl-1, Pim-1, Survivin in OSCC cells[3].
MPT0B098 (0.25 μM; 15-240 min) gradually reduces phosphorylation and total protein levels of JAK2, TYK2 and STAT3 without altering STAT3 mRNA expression[3].
MPT0B098 (0.25 μM; 0-60 min) selectively upregulates SOCS2 and SOCS3 protein levels rather than PIAS1/3 and SOCS1 in OSCC cells[3].
MPT0B098 (0.25 μM) combined with 5 μM Cisplatin (HY-17394) or 5 μM 5-FU (HY-90006) produces markedly stronger proliferation inhibition and caspase-3 activation effects in OEC-M1 cells compared with single drug treatment[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:A549
-
Concentration:75, 150, 300, 450, 600 nM
-
Incubation Time:24 h
-
Result:Induced G2/M phase arrest in a concentration-dependent manner.
Increased the G2/M phase population with a concomitant loss of the G0/G1 phase, increased cyclin B1 and MPM2 levels, shifted Cdc25C phosphorylation status, and increased hypophosphorylated Cdc2.
-
Cell Line:A549
-
Concentration:150, 300, 600 nM
-
Incubation Time:24 h
-
Result:Increased TUNEL-positive apoptotic cells in a concentration-dependent manner.
Increased the TUNEL-positive population from 1% in control cells to 4.9%, 24.7% and 78.7% at 150 nM, 300 nM and 600 nM, respectively.
Induced Bcl-2 phosphorylation and PARP cleavage.
-
Cell Line:HUVEC
-
Concentration:0.25 μM
-
Incubation Time:24 h
-
Result:Inhibited VEGF-induced HUVEC migration without compromising HUVEC viability.
-
Cell Line:A549
-
Concentration:0.1, 0.3, 0.6, 0.9, 1.2 μM
-
Incubation Time:18 h
-
Result:Reduced hypoxia-induced HIF-1α protein expression in a concentration-dependent manner.
-
Cell Line:A549
-
Concentration:0.3, 0.6, 0.9 μM
-
Incubation Time:24 h
-
Result:Reduced HIF-1α mRNA levels under hypoxic conditions, whereas colchicine did not reduce HIF-1α mRNA levels under the same experimental condition.
-
Cell Line:A549
-
Concentration:600 nM
-
Incubation Time:6, 12, 18 h
-
Result:Reduced cytoplasmic HuR distribution and decreased HIF-1α expression under hypoxic conditions.
-
Cell Line:OEC-M1 under normoxic /hypoxic conditions
-
Concentration:111, 222, 444 nM
-
Incubation Time:72 h
-
Result:Inhibited OEC-M1 cell proliferation under normoxic and hypoxic conditions, and exerted weaker hypoxia-induced drug resistance.
-
Cell Line:OEC-M1
-
Concentration:111, 222, 444 nM
-
Incubation Time:18 h under hypoxia; 36 h under hypoxia; 18 h drug pretreatment + subsequent 18 h TGF-β co-stimulation under hypoxia
-
Result:After 18 h hypoxic treatment, dose-dependently downregulated HIF-1α protein, blocked hypoxia-triggered F-actin cytoskeleton rearrangement and reduced hypoxia-induced FAK phosphorylation without changing total FAK protein levels.
After 18 h and 36 h hypoxic treatment respectively, suppressed EMT transcription factors Twist and SNAI2/Slug.
After 36 h hypoxic treatment, downregulated mesenchymal markers vimentin and N-cadherin, partially restored epithelial marker E-cadherin, decreased TGF-β protein expression and inhibited Smad2/3 phosphorylation.
After 18 h hypoxic drug pretreatment followed by another 18 h TGF-β co-stimulation under hypoxia, reversed TGF-β-triggered Smad2/3 phosphorylation in hypoxic OEC-M1 cells.
-
Cell Line:OEC-M1 under hypoxic conditions
-
Concentration:111, 222, 444 nM
-
Incubation Time:36 h
-
Result:Decreased mRNA transcription levels of TGF-β1 and TGF-β2 in hypoxic OEC-M1 cells.
-
Cell Line:OEC-M1 under hypoxic conditions
-
Concentration:111nM
-
Incubation Time:48 h
-
Result:Reversed hypoxia-induced mesenchymal fibroblast-like morphological transformation of OEC-M1 cells.
-
Cell Line:OEC-M1 under hypoxic conditions
-
Concentration:4 h, 6 h, 8 h, 18 h
-
Incubation Time:48 h
-
Result:Time-dependently inhibited hypoxia-induced OEC-M1 cell migration without obvious cytotoxicity, and its anti-migration activity was superior.
-
Cell Line:OEC-M1
-
Concentration:0.25 μM, 0.5 μM
-
Incubation Time:12 h
-
Result:Induced dose-dependent G2/M phase cell cycle arrest in OEC-M1 cells.
-
Cell Line:OEC-M1, HSC-3, DOK, YD-15
-
Concentration:0.12 μM, 0.25 μM, 0.5 μM, 1 mM
-
Incubation Time:24 h
-
Result:Induced concentration-dependent cell apoptosis.
Elevated activated caspase-3 and cleaved PARP.
Downregulated anti-apoptotic proteins including Bcl-2, Mcl-1, Pim-1 and Survivin.
-
Cell Line:OEC-M1, HSC-3
-
Concentration:0.25 μM
-
Incubation Time:15 min, 30 min, 60 min, 120 min, 240 min
-
Result:Time-dependently decreased phosphorylation and total protein levels of JAK2, TYK2 and STAT3 without altering STAT3 MRNA.
Selectively upregulated SOCS2 and SOCS3 protein while SOCS1, PIAS1 and PIAS3 kept stable expression.
Prolonged the half-life of SOCS3 protein, strengthened the binding between SOCS3 and JAK2/TYK2, and promoted the ubiquitination and degradation of JAK2 and TYK2.
-
Cell Line:OEC-M1
-
Concentration:0.25 μM
-
Incubation Time:24 h, 48 h, 72 h
-
Result:The combination with 5μM cisplatin (HY-17394) or 5μM 5-FU (HY-90006) produced stronger growth inhibition and higher caspase-3 activity.
-
Cell Line:OEC-M1, HSC-3
-
Concentration:0.25 μM
-
Incubation Time:24 h co-culture with IL-6
-
Result:Suppressed IL-6-induced JAK2/STAT3 phosphorylation and reversed IL-6-mediated apoptosis inhibition of oral cancer cells.
-
Cell Line:Plasmid/shRNA transfected for 48 h in OEC-M1, HSC-3, DOK, YD-15
-
Concentration:0.25 μM
-
Incubation Time:24 h
-
Result:SOCS3 overexpression enhanced MPT0B098-triggered caspase-3 activity, while SOCS3 knockdown weakened the pro-apoptotic effect; STAT3 silencing sensitized OSCC cells to cytotoxicity.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Five-week-old nude mice subcutaneously implanted with A549 cells (2 × 106 cells) into the right flank region[1]
-
Dosage:25, 50 mg/kg
-
Administration:Intraperitoneal injection (i.p.); once daily; for 5 consecutive days
-
Result:Intraperitoneal injection (i.p.); once daily; for 5 consecutive days Delayed A549 xenograft tumor growth in a dose-dependent manner.
Reduced CD31-positive microvessel density in tumor specimens.
Was well tolerated up to 50 mg/kg.
Caused no obvious signs of toxicity in drug-treated mice.
Maintained body weight loss within 15% in all treatment groups.
Chemical Information
-
CAS No. 1254363-89-7
-
Masse moléculaire 366.44
-
Formule C20H18N2O3S
-
SMILES
O=S(=O)(C1=CC=C(OC)C=C1)N2C3=C(C=CC=C3CC2)C=4C=CN=CC4
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
[1]. Cheng YC, et al. MPT0B098, a novel microtubule inhibitor that destabilizes the hypoxia-inducible factor-1α mRNA through decreasing nuclear-cytoplasmic translocation of RNA-binding protein HuR. Mol Cancer Ther. 2013;12(7):1202-1212. [Content Brief]
[2]. Tsai IT, et al. Novel microtubule inhibitor MPT0B098 inhibits hypoxia-induced epithelial-to-mesenchymal transition in head and neck squamous cell carcinoma. J Biomed Sci. 2018;25:28. PMID: 29592811. DOI: 10.1186/s12929-018-0432-6. [Content Brief]
[3]. Peng HY, et al. MPT0B098, a microtubule inhibitor, suppresses JAK2/STAT3 signaling pathway through modulation of SOCS3 stability in oral squamous cell carcinoma. PLoS One. 2016;11(7):e0158440. PMID: 27367272. DOI: 10.1371/journal.pone.0158440. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
MPT0B098 Related Classifications
HY-124595 Related Classifications
Powered by Bioz
- MPT0B098
- 1254363-89-7
- Microtubule/Tubulin
- HIF/HIF Prolyl-Hydroxylase
- TGF-beta/Smad
- STAT
- JAK
- Apoptosis
- microtubule inhibitor
- Tubulin inhibitor
- colchicine-binding site
- Tubulin polymerization
- HIF-1α
- HuR
- HIF-1α mRNA stability
- VEGF
- angiogenesis
- HUVEC
- A549
- H460
- H1299
- HONE-1
- PC-3
- KB
- HT29
- MKN-45
- OEC-M1
- HSC-3
- SCC-15
- HOK
- hypoxia
- EMT
- vimentin
- N-cadherin
- E-cadherin
- Twist
- SNAI2
- Slug
- TGF-β
- Smad2
- Smad3
- FAK
- F-actin
- SOCS3
- JAK2
- TYK2
- STAT3
- ubiquitination
- cisplatin
- 5-FU
- A549 xenograft model
- microvessel density
- Inhibitor
- inhibitor
- inhibit